CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

CalciMedica (CALC) management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

CalciMedica (CALC) management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.

The chat is scheduled for 9:30 a.m. ET. A live webcast will be available through the company's IR Events and Presentations website section, with a replay archived on its website for 90 days.

Key Terms

crac channel

1 terms

crac channel technical

"calcium release-activated calcium (CRAC) channel inhibition therapies"

A CRAC channel is a specific type of protein pore in cell membranes that opens to let calcium enter cells after internal calcium stores are depleted, helping trigger processes like immune cell activation and secretion. Investors pay attention because drugs or diagnostics that block or modulate these channels can change how the immune system, inflammation, allergy, or certain cancers behave, so breakthroughs or setbacks in CRAC-targeting therapies can affect company value much like a new valve changing flow through a pipe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 08:00 AM EST

LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 9:30 a.m. ET.

A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company's pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PH and a planned Phase 2b trial in acute pancreatitis. CM5480 is also being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.

Investor Relations Contact
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com